Background: Influenza vaccination is recommended to cancer patients undergoing chemotherapy, but vaccine coverage remains low. During the 2009 influenza pandemic, French recommendations were to vaccinate immunocompromised patients with two doses of adjuvanted vaccine. This study aimed to evaluate vaccine immunogenicity in cancer patients receiving chemotherapy.
introduction
Influenza and influenza-associated infections are responsible for an increased mortality rate in patients with cancer compared with the general population [1] . Influenza vaccination can significantly reduce morbidity and mortality in non-immunocompromised subjects [2] . Although immunogenicity is reduced in cancer patients [3] , vaccination is recommended; however, only a low rate of influenza vaccination is carried out in these patients [4] . To date, the optimal timing for vaccination of patients receiving chemotherapy remains unclear. To our knowledge, the only publication on this topic stated that the immunogenicity of the influenza vaccine was increased when the vaccine was administered between courses of chemotherapy [5] .
In 2009, the circulation of the novel A/H1N1v influenza virus and its potential severity in immunocompromised patients led the French authorities to recommend two doses of adjuvanted H1N1v vaccine, with a 21-day interval between, for cancer patients receiving chemotherapy [6] . Recommendations were to vaccinate at least 7 days after last administration of chemotherapy with a first dose of adjuvanted H1N1v vaccine, followed by a second dose at 3 weeks later. Because no data were available on immunogenicity in cancer patients treated with cytotoxic drugs and/or targeted therapies, we conducted a prospective study to evaluate the immunogenicity and safety of this new influenza vaccine in cancer patients receiving different chemotherapy schedules and/or targeted therapies. We focused on the type (cytotoxic versus targeted treatment) and schedules of chemotherapy treatments (every 3 weeks, 2 weeks, weekly, or continuously).
patients and methods

study design and population
This prospective study was conducted in two teaching hospitals in Paris, France. The main objective of the study was to assess the immunogenicity of one and two doses of an AS03A-adjuvanted H1N1v influenza vaccine. Secondary end points were to evaluate the impact of frequency and type of chemotherapy on immunogenicity and to assess the vaccine's safety.
Patients were eligible to participate in this study if they were ‡18 years, had a histologically proven cancer, were receiving a chemotherapy and/or a targeted therapy for a solid tumour, had an expected lifetime of at least 12 weeks, and a performance status score of between zero and two. Exclusion criteria were a potential indication to change chemotherapy treatment in the 42 days following the first injection (to avoid bias related to any therapy changes), an allergy to egg proteins, a previous history of allergy to any influenza vaccine component, current acute febrile disease at the time of enrolment, history of clinically or virologically confirmed influenza infection in the previous 6 months, pregnant or lactating women, a contraindication to intramuscular injections, any other immunosuppressive disease (such as human immunodeficiency virus infection, viral hepatitis B or C infection, solid-organ transplantation, Child C cirrhosis), and any other immunisation carried out in the 3 weeks before the first injection or planned in the following month.
Patients were grouped according treatment frequency: patients receiving chemotherapy every 3 weeks (group 3W), patients receiving chemotherapy every 2 weeks (group 2W), patients receiving chemotherapy weekly or daily (group C), and patients only treated with targeted therapies, whatever the periodicity (group T). Groups 3W and 2W received the first vaccine dose on day 7 of the chemotherapy. The second dose was carried out 3 weeks after, as recommended by the European Medicine Agency and the French authorities. Blood samples for assessment of haemagglutination-inhibited [7] antibodies against AH1N1v were taken before vaccination and at 3 weeks following each vaccination. Sera were stored frozen at 220°C until analysed.
Written informed consent was obtained from each patient. The protocol was conducted in accordance with the Declaration of Helsinki and the French law for biomedical research and was approved by the Committee for Protection of Persons.
study vaccine
The study vaccine was PandemrixÒ (GlaxoSmithKline Biologicals, Rixensart, Belgium), a monovalent A/H1N1v-inactivated influenza vaccine, containing the AS03A oil-in-water adjuvant. This pandemic vaccine was licenced for the 2009-2010 season and contained 3.75 lg of haemagglutinin antigen of the A/California/7/2009 (H1N1) strain. Vaccines were packaged in multidose vials and administered intramuscularly (0.5 ml) in the deltoid muscle using a standard sterile technique.
safety surveillance
Patients were observed for a 30-min period after immunisation to detect hypersensitivity reactions or other immediate adverse reactions. They were then provided with a reporting card and received instructions on how to record the maximum daily measurement or maximum severity of any injection site reaction (swelling, tenderness, induration, redness) and/or any systemic reaction (fever, fatigue, chills, malaise, myalgia, arthralgia, headache, nausea/vomiting, sweating) for 21 days after each vaccination. The severity of vaccine-related adverse events was graded as mild (transient discomfort without limitation of normal daily activities, no medical intervention or treatment required), moderate (mild to moderate limitation of normal daily activities, minimal medical intervention required), or severe (marked limitation of normal daily activities, medical intervention and corrective treatment required, possible hospitalisation). Antibody titres against H1N1v were tested by a haemagglutination inhibition (HI) test [7] on days 1 (D1), 21 (D21), and 42 (D42). Briefly, sera were treated with receptor-destroying enzyme 5to remove non-specific inhibitors. Twofold dilutions of treated sera, beginning at 1 : 10, were tested against four haemagglutinin units of antigen (PanenzaÒ H1N1 vaccine; Sanofi Pasteur, Lyon, France) on human O Rh2 red blood cells. The titre of HI antibodies was defined as the reciprocal of the highest serum dilution that completely inhibited haemagglutination. All the sera from an individual patient were analysed on the same microtitre plate. Sera, whose titres were <10, were assigned a titre of 5 for calculation purposes.
immunogenicity assessment
Immunogenicity was assessed according to the criteria of the European Committee for Proprietary Medicinal Products [8] . The primary end point was defined as immunogenicity observed on days 21 and 42. Seroprotection rate (SPR) was defined as the proportion of subjects with a serum HI antibody of at least 1 : 40, considered as the threshold for effective protection; the seroconversion rate (SCR) was defined as the proportion of patients with a fourfold or greater increase in HI antibodies between baseline and day 21 or day 42 and the seroconversion factor (SCF) as the fold increase in HI antibody titre at postvaccination (postvaccination antibody titre divided by the prevaccination titre).
statistical analyses
Categorical variables were described as frequencies and percentages and continuous variables as means 6 standard deviation. Categorical variables were compared using the chi-square test or Fisher's exact test and by Wilcoxon signed rank test or Kruskal-Wallis tests for continuous variables. Differences at P < 0.05 were considered statistically significant. The study included all patients who had received at least one dose of vaccine. Immunogenicity studies on D21 and D42 included patients who received one dose of vaccine and two doses of vaccine, respectively. Because of the differences in the mean age among the four groups of treatments, we carried out uni-and multivariate analyses on the treatment groups and mean ages (<65 and ‡65 years), considering group T as the reference.
results
patients' characteristics
A study flow chart is presented in Figure 1 . Among the 84 vaccinated patients, 9 patients were vaccinated but refused serological tests. Thus, 75 patients consented to participate in the study, of whom 65 (86.7%) received two doses of vaccine and represented the study population. Follow-up data at D42 were unavailable for 21 patients (32.3%): 4 patients died of cancer, 6 missed the follow-up (1 travelled abroad, 2 changed oncology centre, and 3 for unknown reason), and 11 stopped or changed their cancer treatment because of an unforeseeable progression of cancer or a curative surgical procedure. The patients' characteristics are presented in Table 1 . The overall mean age was 64.6 6 10 years (minimum-maximum: 33-85). Forty-nine (75.4%) patients had metastatic disease, 56 (86.2%) had received at least one cytotoxic drug, 29 (44.6%) a monoclonal antibody, and 5 (7.7%) a multikinase inhibitor. Twelve (18.5%) had received a cytotoxic regimen every 3 weeks (group 3W), 36 (55.4%) a cytotoxic regimen every 2 weeks (group 2W), 8 (12.3%) were receiving continuous oral cytotoxic drugs or a weekly cytotoxic regimen (group C), and 9 (13.9%) were receiving a targeted therapy alone (monoclonal antibody or multikinase inhibitor) (group T). Details of the chemotherapy schedules, demographic data, and immunogenicity results for each patient are shown in Table 2 .
immunogenicity. Table 3 shows the immunogenicity results. At baseline, only three (4.6%) patients had HI antibodies against the A/California/7/2009 (H1N1v) strain with titres of ‡1 : 40, which may represent exposition to the A/H1N1v virus or in vitro cross reactivity. SCRs were 44.4% and 72.7% at D21 and D42, respectively, indicating the percentage of patients who had an immune response to the vaccine. SCFs were 4.71 6 3.8 at D21 and 8.5 6 3.9 at D42, representing the intensity of immune response to the vaccine in terms of a fold increase in antibody titre against the influenza virus.
safety analysis. Table 4 shows the adverse events reported on D21. Sixty-three patients (97%) entered vaccine safety data on D21; safety data were missing for two patients. Solicited local reactions were all mild or moderate, and systemic reactions were mainly mild or moderate. Two (3.8%) patients reported reactions potentially related to the anticancer drug treatment. Safety data on D42 showed that mild and moderate adverse events occurred with the same intensity and frequency as on D21, and no severe reactions related to the study vaccine were observed (data not shown).
subgroup analysis. Table 5 shows the characteristics and immunogenicity results for the four groups of anticancer treatments. Some characteristics of the patients were significantly different between the four groups: gender, age, granulocyte colony-stimulating factor (GCSF) use, and multikinase inhibitor treatment ( Table 5 ). The significant difference in the use of GCSF was related to the difference in the immunosuppressive properties of the different chemotherapies. On D21, SCRs were significantly lower in patients receiving cytotoxic drugs every 3 weeks or every 2 weeks (45.5% in group 3W and 30.6% in group 2W) compared with patients receiving continuous cytotoxic treatment or targeted therapy alone (71.4% in group C and 77.8% in group T) (P = 0.029). This difference was not found on D42 (P = 0.12), but the intensity of the response to the vaccine, as shown by geometric mean titers and SCFs at D42, was associated with the treatment group, with lower SCFs in groups 3W and 2W than in groups C and T (8.83 6 2.32 in group 3W, 5.33 6 3.57 in group 2W, 38.43 6 5.17 in group C, and 10.77 6 2.85 in group T; P = 0.036). A lower SCR in patients receiving a cytotoxic drug every 2 weeks was observed (58Á3%). For details about immunogenicity for each group, see Table 2 .
Immunogenicity response to vaccination in elderly healthy subjects is usually lower than in younger subjects. Results are shown in Table 6 . Cytotoxic treatment each 2 weeks was significantly associated with a lower SCR (P = 0.009). This association remained significant when adjusted for age [odds ratio (OR) of 0.11, 95% confidence interval (CI) 0.02-0.64, P = 0.007] and for both age and gender (P = 0.021, data not shown). Seroconversion at D21 was negatively associated with the 3W and 2W groups compared with the groups C and T (OR 0.17, 95% CI 0.05-0.62, P = 0.007). By D42, there was no : patients received at least one cytotoxic drug continuously or weekly 6 targeted therapies; Group 4(T): patients received targeted therapies alone (monoclonal antibodies and/or multikinase inhibitors); Metastatic: 0 means that patient was in an adjuvant setting, 1 at least one metastatic site, which corresponds to at least the minimal titre considered to be sufficient to protect against the influenza virus (a titre of 1 : 40 in the haemagglutination inhibition test), 1 means that the titre was at least 1 : 40, 0 means that titre was insufficient to confer protection against influenza; SP D1: seroprotection at day 1 before vaccination; SP D21: seroprotection at 21 days after the first dose of vaccine and before the second dose; SP D42: seroprotection at 21 days after the second dose of vaccine; NA: not available because the patient was lost to follow-up, died before the blood test or changed treatment. Cases shaded grey indicate patients protected against the influenza virus. SP, seroprotection; F, female; M, male. CPT11, irinotecan; Xelox, capecitabine oxaliplatin; ACUP, adenocarcinoma of uknown primary; GIST, gastrointestinal stromal tumor. 
discussion
This study, which evaluated the immunogenicity (within the French guidelines) of vaccination against 2009 H1N1v in immunocompromised patients treated with anticancer drugs, showed that immunogenicity of one dose of vaccine was globally low (SPR: 47.6%), especially in patients treated with cytotoxic drugs given every 3 weeks or every 2 weeks. A second dose of vaccine induced a higher level of immunogenicity (SPR: 72.7%). This rate is comparable to that found in studies that evaluated the immunogenicity of unadjuvanted influenza vaccine before the influenza pandemic [3] . In contrast, SCRs after one dose of AS03-adjuvanted vaccine in healthy volunteers was found to be 98.2%. This suggests that the chemotherapies induced deep immunosuppression and dramatically affected the response to the vaccine [9] . At D21, results of univariate analysis showed a significantly lower SCR in patients treated every 2 weeks compared with the control group (30.6%). A statistical significance was not reached between 3W and the control, probably because of the low number of patients in the 3W group. Receiving a cytotoxic treatment, every 2 weeks was associated with a low SCR on D21 (OR = 0.13, 95% CI 0.02-0.71, P = 0.009), even after adjustment for age.
By D42, SCR was acceptable to protect against H1N1v in all groups, though there was a lower rate in group 2W (58.3%). A hypothesis is that the second vaccination was carried out just after administration of chemotherapy (cycles of chemotherapy were on D14 and D28, and vaccinations were on D7 and D28). SCR on D42 was associated with age (<65 versus ‡65 years) but not with treatment group. However, the number of patients might have been insufficient to show a significant difference, and the mean age of patients in group 2W was higher given the large proportion of colorectal cancers included in this group. Usual regimens in colorectal cancer are scheduled over 2 weeks [10, 11] . Age differences between the groups might explain the difference in SCR in this group at D42, more than the frequency of cytotoxic chemotherapy, as being older is associated with a lower response to vaccination [12] . GCSF use could be a confounder since it may affect the immune response. However, this hypothesis was specifically tested and no difference was found between the four groups. There was no significant difference according to the primary cancer throughout the population. It is difficult to say whether the lack of immunisation response was related to the treatment itself or to its periodicity. Nevertheless, we can see the following from Table 2 , which details responses by type of chemotherapy. (i) For group 3W patients, those receiving docetaxel had a lower SCR on D21 than patients receiving chemo-based platinum salts. However, these observations are limited by the small number of patients. (ii) For the 2W group, no patients receiving GEMOX or gemcitabine fixed-dose-rate (FDR) had become seroconverted by D21. In comparison, it seems that patients receiving LV5FU2 (leucovorin 400 mg/m 2 , 5FU bolus 400 mg/m 2 , 46-h infusion of 5FU 2400 mg/m 2 ) had mostly become seroconverted compared with 4 of 11 patients receiving FOLFOX 85 (LV5FU2 combined with Oxaliplatin 85 mg/m 2 ), 0 of 3 receiving FOLFIRI 1 (LV5FU2 combined with Irinotecan 180 mg/m 2 ), 0 of 3 receiving FOLFOX 100, and 1 of 5 receiving Data are the number of cases (%). Total for 'any reaction' may be lower than the total of all the adverse effects because one patient may present with several adverse events at the same time.
Not related: another cause of events is more plausible, and/or a clinically plausible temporal sequence is inconsistent with the onset of the event and the vaccine administration, and/or a causal relation is considered biologically implausible. It seems that the type of chemotherapy on D21, even though difficult to demonstrate because of lack of statistical power, affected seroconversion. Adjustment for age on D21 has been given for those aged <65 years and for those ‡65 years in age. Adjustment for group D42 was given to treatment groups 3W + 2W, and C + T. Bold characters are used to highlight the statistically significative results. OR, odds ratio; CI, confidence interval.
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To summarise, the second dose of adjuvanted vaccine improved immunogenicity and was necessary to achieve adequate anti-influenza protection. Age was also an important factor that needs to be taken into account before planning influenza vaccination for a cancer patient.
The optimal vaccination schedule for patients receiving chemotherapy remains to be determined. Hence, patients in groups 3W and 2W achieved low SCRs when vaccinated at D7 after chemotherapy administration. Whether earlier administration could result in enhanced immunogenicity should be investigated in further studies.
Safety data showed that the AS03-adjuvanted vaccine had a lower tolerance profile than the trivalent-inactivated influenza vaccine in cancer patients [13] . In healthy volunteers, the adjuvanted H1N1v vaccine is known to cause more adverse events, mainly mild to moderate, than the unadjuvanted vaccine [9] . All systemic adverse events could be related to chemotherapy since recall bias may have occurred. We could not exclude the possibility that the vaccine increased fatigue, and this point should be taken into account when considering vaccinating a cancer patient. This is the first report on vaccine immunogenicity in patients treated with multikinase inhibitors and monoclonal antibodies for non-haematological malignancies. The present study shows that targeted therapies associated with cytotoxic drugs did not seem to affect immunogenicity, unlike previous reports in patients receiving rituximab for rheumatoid arthritis [14] . Patients on targeted therapy alone, especially multikinase inhibitors, have better results than other groups. Targeted therapies often act on ubiquitous transduction pathways that can be important in the immune process and lead to antibody production, such as activation of dendritic cells or B lymphocytes [12, [15] [16] [17] .
The main limitation of our study was the low number of patients, especially in the group treated with multikinase inhibitors. Another limitation of the study is that immunogenicity was assessed at only D21 and D42. It would be interesting to evaluate, in further studies, the persistence of antibodies at 3-6 months after vaccination, to better describe the kinetics and the protection induced by the vaccine. Such studies will have to take into account the life expectancy of the patients and the timing of the influenza epidemic.
If confirmed by others, the present results may have important consequences regarding vaccine-related immunity in the context of highly immunosuppressant patients. Future development of vaccines for immunosuppressed patients should consider the use of an adjuvant, which could play a positive role in aiding immunotherapy during cancer.
Finally, our results show that adjuvanted influenza vaccination in patients with solid tumours is safe but suggest that a single dose of adjuvanted vaccine is insufficient to confer acceptable protection against influenza in patients receiving cytotoxic drugs. Two doses of adjuvanted vaccine improved immunogenicity results in this population. The first data on immunisation of patients receiving targeted therapies are promising, as one dose of vaccine showed satisfying results. However, future studies are needed to evaluate the immunogenic strategies for seasonal influenza vaccination in patients undergoing cancer treatment.
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